Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Autolus Therapeutics to host Investor Conference Calls through June
26 mai 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 26, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020
22 mai 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...
Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting
15 mai 2020 11h20 HE
|
Autolus Therapeutics plc
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held Thursday, June 25,...
Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting
15 mai 2020 07h00 HE
|
Autolus Therapeutics plc
– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held...
Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program
14 mai 2020 07h00 HE
|
Autolus Therapeutics plc
- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30...
Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress
07 mai 2020 07h00 HE
|
Autolus Therapeutics plc
- Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company...
Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7
01 mai 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
16 avr. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
11 mars 2020 07h00 HE
|
Precision Biosciences
DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
10 mars 2020 07h05 HE
|
Precision Biosciences
-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical...